Pharma Industrial India Magazine - July - August 2024

The Counterfeit Crisis: A Call to Action for the Pharmaceutical Industry In today’s rapidly advancing technological landscape, the pharmaceutical industry is confronted with a critical chal- lenge: counterfeit drugs. While innovations are transforming medicine, they also introduce new vulnerabilities in an indus- try where authenticity and safety are paramount. Counterfeit drugs pose a serious threat that goes beyond financial losses; they jeopardize public health and undermine trust in the medi- cal system. Ensuring that counterfeit drugs do not infiltrate the market is a crucial aspect of quality assurance. Every medi- cation produced must be genuine, safe, and effective, safe- guarding both the industry’s reputation and public health. The issue of counterfeit drugs underscores the need for strin- gent quality assurance practices. Counterfeit medications endanger patients, leading to ineffective treatments, adverse reactions, or even death. This problem transcends protecting profit margins; it is fundamentally about maintaining trust in the safety and efficacy of medications. To uphold the industry’s commitment to high-quality treatments, it is essential to guar- antee the authenticity of every drug throughout the entire pro- duction and distribution process. This dedication to quality is vital for safeguarding public health and preserving the integrity of the pharmaceutical sector. The pharmaceutical supply chain is complex, involving nu- merous stages from raw material sourcing to the final product reaching consumers. This complexity creates opportunities for counterfeiters to exploit weaknesses and introduce fake drugs. To combat this issue, comprehensive measures must be imple- mented at every stage of the supply chain, from pre-produc- tion to post-production. Ensuring drug authenticity begins with secure raw materi- al sourcing from reputable suppliers. During manufacturing, stringent monitoring and unannounced inspections are essen- tial. Advanced analytics can detect anomalies in production data that may indicate fraudulent activities, helping maintain the integrity of the manufacturing process. Following produc- tion, securing distribution channels and conducting regular checks are necessary to prevent counterfeit drugs from enter- ing the supply chain. Comprehensive end-to-end serialization enhances traceability, allowing for the tracking of each unit from the manufacturer to the patient, making it easier to identify and remove counterfeit products. Technological advancements offer powerful tools to combat counterfeit drugs. Blockchain technology provides a secure, immutable record of a drug’s journey from the manufacturer to the consumer, significantly reducing the risk of counterfeit products infiltrating the supply chain. The rise of “phygital” solutions—combining physical and digital technologies—has introduced innovative methods for combating counterfeiting. QR codes linked to blockchain verification systems, holo - graphic seals, and DNA tagging create multiple layers of se- curity, making it increasingly difficult for counterfeiters to suc - ceed. The International Organization for Standardization’s ISO 22383 guidelines provide a valuable framework for developing and implementing anti-counterfeiting measures, emphasizing robust authentication solutions and supporting standardized practices across the industry. Despite these technological advancements, combating coun- terfeit drugs requires more than just new tools. A shift in regu- latory practices and oversight is necessary. Traditional meth- ods of relying solely on scheduled inspections and paper trails are no longer sufficient. More frequent, unannounced Manoj Kochar President ASPA ANRETWICSLE PHARMA INDUSTRIALINDIA · JUL-AUG 24 22